Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Anika Therapeutics, Inc. reported revenue of $113M, down 5.9% year over year. Operating margin was -9.8% and net margin -9.6%, on a free-cash-flow margin of 3.9% with capital expenditure at 6.1% of revenue. Every figure is computed directly from ANIK's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $113M | -9.8% | -9.6% |
| FY2024 | $120M | -4.3% | -47.0% |
| FY2023 | $121M | 0.7% | -68.4% |
| FY2022 | $114M | 3.2% | -13.1% |
| FY2021 | $148M | 1.8% | 2.8% |
How does ANIK compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.